RSV: The New Vaccine Set to Prevent Severe Illness in Infants and Seniors
A new vaccine for Respiratory Syncytial Virus (RSV Vaccines) has shown promise in preventing severe illness in seniors and infants, according to a recent study published in the New England Journal of Medicine. RSV is a common respiratory virus that can cause severe illness, especially in older adults and infants. It is estimated that RSV is responsible for around 177,000 hospitalizations and 14,000 deaths among older adults each year in the United States alone. The new vaccine, developed by pharmaceutical company Novavax, targets the F protein of RSV, which is a major target for the immune system. The vaccine uses a nanoparticle technology, which has been shown to elicit a strong immune response in preclinical studies. What were the results of the clinical trial? The clinical trial, which involved over 5,000 participants, found that the vaccine was highly effective in preventing severe RSV illness in older adults and infants. The vaccine was shown to be 60% effective in preventin...